EVO756 (MRGPRX2 Antagonist)

May 7, 2026 — Evommune, Inc. (NYSE: EVMN) reported first-quarter 2026 financial results (ended March 31, 2026) and outlined upcoming clinical milestones for its inflammation-focused pipeline. Lead program EVO756 (oral MRGPRX2 antagonist) has completed enrollment in two Phase 2b dose-ranging trials: chronic spontaneous urticaria (CSU; N=160) with top-line data expected in June 2026, and atopic dermatitis (AD; N=120) with top-line data expected in 3Q 2026. The company also plans to initiate a Phase 2b dose-ranging trial of EVO756 in migraine prophylaxis in mid-2026, with top-line data anticipated in 2027, and will present translational/preclinical data at AHS (June 2026) and FOCIS (June 2026). For EVO301 (injectable IL-18 binding protein fusion), Evommune completed high-concentration subcutaneous formulation work and initiated manufacturing; a Phase 2b AD trial is planned to start mid-2027, following prior Phase 2a proof-of-concept results (reported Feb 2026). Financially, cash/cash equivalents/investments were $307.0M (vs $216.7M at Dec 31, 2025); Q1 revenue was $0 (vs $3.0M in Q1 2025); net loss was $21.7M (vs $14.6M). The company expects cash runway through 2028.